Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Tekon Biotech as its exclusive distributor in China, including Hong Kong and Taiwan.Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Tekon Biotech as its exclusive distributor in China, including Hong Kong and Taiwan.
Sunnyvale, CA — August 11, 2009 — Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Tekon Biotech as its exclusive distributor in China, including Hong Kong and Taiwan.
“Tekon, one of the leading distributors in China, will be a great partner for us,” said Stephen Bates, Sr. Vice President of Sales, Marketing and Service of Labcyte Inc. “As we expand in Asia, Tekon will help us broaden our existing user base in the pharmaceutical industry and the contract research organizations (CROs) that service them. Tekon will provide them with technology from Labcyte for industry-leading compound management, high-throughput and secondary screening. Our established customers in China will find that Tekon will give them an opportunity for more immediate support and interaction. Tekon will also introduce us to new users in the growing genomics market. We feel that with the Labcyte platforms, Tekon can meet the genomics customers’ needs for miniaturization, precision and accuracy while remaining contamination-free.”
“We are very excited to be chosen by Labcyte as their partner in China, it is a tremendous validation of our efforts to provide the best possible support to our customers” said David Hadfield, CEO of Tekon Biotech. “We see a great potential market for low-volume transfer devices in China. We believe that the growing genomics markets, especially for gene expression, SNP analysis and RNAi, will find that the need for miniaturization is met particularly well by the Labcyte technologies. It is our goal to represent only the industry leading products in every category. Labcyte offers unique, touchless liquid handling systems. Our customers will have optimal interactions with a local group while reaping the benefits of the best available technology.”
“As the market moves to higher-density assays, the touchless liquid handling capabilities offered by the Labcyte acoustic products becomes essential,” said Dr. Nick Samaras, Labcyte Managing Director, Asia-Pacific. “In particular, our Echo®
liquid handler provides superior results, reduces costs by eliminating consumables and reduces toxic wastes. Our platform technology is also being applied in other fields such as array formation, the microencapsulation of compounds, particle production, proteomics research, the transfer of ultra-viscous materials, cell-based biology and imaging mass spectrometry.”
About Tekon Biotech
Tekon Biotech, founded in 1988, sells and supports a broad range of technologies to the China life sciences market. Tekon’s customers include all the major pharmaceutical and biotech companies plus the top 50 universities. Tekon is headquartered in Shanghai with offices in Hong Kong and Taipei. Tekon Biotech takes pride in providing the best service and technical support. For more information, visit www.tekontech.com
About Labcyte Inc.
Labcyte Inc. uses sound to move liquids. This green technology provides significantly better analytical results while saving money. The ‘touchless’ technology provides dramatically better answers by eliminating pipette tips and the adsorption of compounds during transfer, while saving hundreds of thousands of dollars in decreased consumables. Accuracy is maintained from first drop through last for a wide variety of fluids, including many considered intractable by other techniques. The technology is coupled with our Deerac™ instruments to make Labcyte a leader in liquid handling. Together with the Deerac systems, the award-winning Echo liquid handlers are used in all of the top 10 pharmaceutical companies, as well as in leading academic and research institutions worldwide. Labcyte technologies have broad applications including the fields of compound management, genomics, proteomics, particle manufacturing, encapsulation, imaging mass spectrometry, and live-cell transfer. Labcyte is headquartered in Sunnyvale, California with offices in Dublin, Ireland and has 39 U.S., 7 European and two Japanese patents and additional U.S. and international filings. For more information, visit www.labcyte.com